OCU410 Phase 3 progress and RMAT status drive Ocugen, Inc. commercial push

OCU410 Phase 3 progress and RMAT status drive Ocugen, Inc. commercial push
Ocugen, Inc. secures 130 million financing

Ocugen, Inc. reported several major milestones during its latest earnings call, with CEO Dr. Shankar Musunuri announcing a 130 million dollar financing deal for the second quarter of 2026.

The company also disclosed a binding term sheet to license its OCU400 therapy in the MENA region, advancement of OCU410 to Phase 3 clinical trials with RMAT designation, and ongoing commercial readiness efforts. These strategic moves underline Ocugen, Inc.’s commitment to expanding its portfolio and geographic reach ahead of key regulatory and commercialization decisions.

Earlier, Ocugen detailed the experience of a participant in the OCU400 clinical trial for retinitis pigmentosa. The company has also reported on new gene delivery strategies for brain-targeted therapies in CNS disorders. These initiatives reflect an ongoing focus on advancing gene therapy research across multiple indications.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.